Singapore Health Sciences Authority approved interim authorization of COVID-19 Vaccine Moderna
On Feb. 3, 2021, Moderna announced that the Singapore Health Sciences Authority (HSA) had approved the interim authorization…
-
-
Novavax and Government of Switzerland announced agreement in principle to supply COVID-19 vaccine
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
-
NIH study of Intranasal influenza vaccine spurred strong immune response in Phase 1 study
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
-
BD announced assay for identification of COVID-19 patients at increased risks of intubation available in Europe
On Feb. 3, 2021, BD (Becton, Dickinson) announced the CE mark of BD Multitestﾙ 6-Color TBNK Reagent with…
-
Bristol Myers and Rockefeller University announced license agreement for SARS-CoV-2 meutralizing mAb combination
On Feb. 3, 2021, Bristol-Myers and The Rockefeller University announced an agreement under which Bristol Myers Squibb was…
-
Mateon announced completion of ARTI-19 and publication of positive interim data
On Feb. 2, 2021, Mateon Therapeutics announced that its ARTI-19 trial, evaluating ARTIVeda / PulmoHeal against COVID-19 in…
-
SARS-CoV-2 spike protein licensed by Oragenics from the NIH demonstrated protective immunity in mice
On Feb. 2, 2021, Oragenics announced that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National…
-
VBI Vaccines announced FDA Acceptance of BLA filing for VBIﾒs 3-antigen prophylactic hepatitis B vaccine
On Feb. 2, 2021, VBI Vaccines announced that the FDA had accepted its filing of the Biologics License…
-
Novavax announced MOU to produce COVID-19 vaccine made in Canada
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…
-
Roche announced launch of SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection
On Feb. 1, 2021, Roche announced it had obtained the CE mark for its new SARS-CoV-2 Rapid Antigen…
-
NIH study showed hyaluronan effective in treating chronic lung disease
On Feb. 1, 2021, researchers at the National Institutes of Health and their collaborators found that inhaling unfragmented…
-
Clover and Dynavax announced planned global phase 2/3 efficacy trial of adjuvanted COVID-19 vaccine candidate
On Feb. 1, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced a plan to initiate a global Phase 2/3…
-
Dynavax and CEPI announced $99 million in funding for CpG 1018 adjuvant manufacturing
On Feb. 1, 2021, Dynavax Technologies and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they have entered…
-
Dynavax announced exercise of option to reserve additional CpG 1018 to produce 40 million doses of adjuvanted COVID-19 vaccine candidate
On Feb. 1, 2021, Dynavax Technologies announced Valneva had informed it that the UK Government exercised its option…
-
Pfizer and BioNTech publish preclinical data from investigational COVID-19 vaccine program in Nature
On Feb. 1, 2021, Pfizer and BioNTech announced that preclinical data in non-human primate and mouse models from…
-
Sorrento announced the fourth patient was released from hospital following third infusion of stem cells
On Jan. 31, 2021, Sorrento Therapeutics announced additional positive results from its Phase 1b study of human allogeneic…
-
The CDC required wearing of face masks while on public transportation and at transportation hubs
On Jan. 30, 2021, as the COVID-19 pandemic continued to surge in the U.S., the CDC implemented a…
-
Rigel awarded $165 Million from US DOD for phase 3 clinical trial of Fostamatinib in COVID-19 patients
On Jan. 29, 2021, Rigel Pharma announced it has been awarded $16.5 million by the U.S. Department of…
-
Innovation Pharmaﾒs phase 2 clinical trial of Brilacidin for treating COVID-19 began
On Jan. 29, 2021, Innovation Pharmaceuticals announced that the companyﾒs Phase 2 clinical trial of Brilacidin for treating…
-
Single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of phase 3 ENSEMBLE trial
On Jan. 29, 2021, Johnson & Johnson announced topline efficacy and safety data from the Phase 3 ENSEMBLE…
-
Pfizer and BioNTech published data on COVID-19 vaccine-induced antibodiesﾒ ability to neutralize SARS-CoV-2 UK strain
On Jan. 29, 2021, Pfizer and BioNTech announced that data from an in vitro study on the capability…
-
DNA Genotek’s OMNIgene®·ORAL included in EUA granted to Ambry Genetics for use in COVID-19 RT-PCR saliva test
On Jan. 29, 2021, OraSure Technologies announced its OMNIgene®·ORAL (OM-505) saliva collection kit, a product of subsidiary DNA…
-
COVID-19 | Diagnostics | Disease | NIH | Women's Health
Severe COVID-19 in pregnancy associated with preterm birth, other complications
On Jan. 28, 2021, National Institutes of Health (NIH) researchers reported that pregnant women who experienced severe symptoms…
-
Researchers used patients’ cells to test gene therapy for rare eye disease
On Jan. 28, 2021, scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy…
-
Biotechnology | COVID-19 | WHO
New COVID-19 variants fueling Africa’s second wave
On Jan. 28, 2021, The WHO announced that COVID-19 cases and deaths were surging in Africa as more…
-
South Carolina detected first US cases associated with variant first detected in South Africa
On Jan. 28, 2021, the CDC announced that it had become aware of the first U.S. documented cases…
-
Mammoth Biosciences and Agilent partnered on high-throughput CRISPR-based SARS-CoV-2 diagnostic test
On Jan 28, 2021, Mammoth Biosciences announced a co-marketing agreement with Agilent Technologies to support the anticipated launch…
-
Biotechnology | COVID-19 | FDA
Precipio launched COVID-19 antibody testing at point-of-care
On Jan. 28, 2021, Precipio announced that following receipt of an Emergency Use Authorization from the U.S. Food…
-
Novavax COVID-19 vaccine demonstrated 89.3% efficacy in UK phase 3 trial
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
-
Celsion filed provisional U.S. patent application for broad range of next generation DNA vaccines
On Jan. 28, 2021, Celsion announced the filing of a provisional U.S. patent application for a novel DNA-based,…
